A combined age-related macular degeneration solution and drug delivery system showed promising results in a phase 1b clinical trial, manufacturers MacuCLEAR and Mystic Pharmaceuticals announced. The two firms formed a partnership to conduct clinical trials of the drug and delivery system. Trial results showed that MacuCLEAR's MC-1101, a...

OXiGENE has initiated a phase 2 study of its vascular-disrupting agent ZYBRESTAT (fosbretabulin) for treating patients with polypoidal choroidal vasculopathy (PCV), the company announced in a press release. PCV is a form of choroidal neovascularization characterized by the growth of abnormal blood vessels in the choroid and is similar to wet...

A review of the literature find no evidence from clinical trials on humans of neuroprotective qualities of Alphagan (brimonidine tartrate) in optic nerve and retinal injury. A neuroprotective treatment is designed to increase cell survival by increasing resistance to injury or inhibiting cell death. It has been suggested that neuroprotective...

ESBATech has announced preclinical results, which demonstrate efficacy of topical ESBA105, an anti-Tumor Necrosis Factor (TNF) single-chain antibody fragment, in a model for choroidal neovascularization (CNV). In wet age-related macular degeneration (wet AMD), CNV causes the formation of new blood vessels growing behind the retina, which can...

SARcode Corporation announced today the results of its Phase 1 trial of the safety, tolerability, and pharmacokinetics of SAR 1118 Ophthalmic Solution in healthy volunteers. SAR 1118 was well-tolerated and demonstrated a favorable safety profile when administered by topical ocular instillation. SAR 1118 is a potent novel small molecule...

Interim data from the OMEGA trial have demonstrated that a topically applied drug for treating geographic atrophy had a promising effect on visual acuity, Othera Pharmaceuticals announced in a press release. The drug, called OT-551, inhibits oxidative stress and disease-induced inflammation. OT-551 is the first eye drop to be tested in a...

MacuCLEAR has entered into a collaboration agreement with Mystic Pharmaceuticals to conduct a phase 1/2 clinical trial of its lead compound for treating dry age-related macular degeneration (AMD), according to a press release from MacuCLEAR, the developer of the drug. The trial will evaluate the effects of the compound, called MC1101, when...

The U.S. Patent and Trademark Office has issued Othera Pharmaceuticals the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation involved in age-related macular degeneration and other ocular disorders. U.S. Patent No. 7,442,711 covers several new chemical entities,...